• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

FDA approves prostate cancer drug delivery system

Article

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

The FDA has approved Mixject, a new delivery system for triptorelin pamoate (Trelstar), a palliative treatment for advanced prostate cancer. Mixject combines triptorelin depot, 3.75 mg, and long-acting triptorelin, 11.25 mg, with new features that make preparation, administration, and disposal easier, according to Watson Pharmaceuticals, the manufactuer of triptorelin.

These new features include a smaller, 21-gauge needle for improved patient comfort, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration. The system is specifically designed to encourage compliance with OSHA regulations within the medical community.

Related Videos
Mature woman with her doctor | Image Credit: © pucko_ns - stock.adobe.com
Gary D. Steinberg, MD, an expert on bladder cancer
Jaleh Fallah, MD, answers a question during a Zoom video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.